BRAND_ANALYSIS#ROCHEHEALTH & PHARMA#22 OF 26 IN HEALTH & PHARMAALIGNED
Roche
· Private · Updated 22 Nov 2026 07:19 UTC
#1056 of 1208 overall by tension · #22 of 26 in Health & Pharma
9Aligned
The Balanced
Analysis
Roche comes in at #1056 with cultural 46, business 55 and tension 9, a sober reading for a pharmaceutical giant. Sentiment is 0.00 and no stock movement is recorded, so the scorecard offers no read on pricing, trials or public trust.
IN THE NEWS (93 articles this week)
US FDA approves Roche's oral treatment for advanced breast cancer - Reuters
Roche’s next major breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD - Fierce Pharma
Roche Secures First U.S. Approval for New Breast-Cancer Pill - WSJ